Second direct-acting antiviral therapy for hepatitis C virus infection after umbilical cord blood transplantation: A case report

Onodera, Koichi; Onishi, Yasushi; Inoue, Jun; Tanaka, Yuya; Yonha, Lee; Ichikawa, Satoshi; Fukuhara, Noriko; Yokoyama, Hisayuki; Murai, Kazunori; Masamune, Atsushi; Harigae, Hideo

doi:10.1016/j.jiac.2021.02.002

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Пациент получил повторное лечение с использованием пангенотипной схемы (софосбувир/велпатасвир + рибавирин), после завершения курса достигнут УВО. Этот опыт позволил авторам рекомендовать оценку и подтверждение УВО после терапии HCV-инфекции до проведения ТГСК, а также мониторинг вирусной нагрузки на всех этапах последующей ТГСК и после нее [57].…”

Section: противовирусное лечение хгс у онкогематологических пациентовunclassified

Chronic Hepatitis С and Oncohematological Diseases

Антонова,

Ножкин,

Лиознов

2024

Clinical Oncohematology

View full text Add to dashboard Cite

This review focuses on HCV infection in oncohematological patients. High risk of hepatitis C virus (HCV) infection within this group of patients was proved by a significantly (2.0–2.5 times) higher HCV infection rate in non-Hodgkin’s lymphoma patients compared to population data. Besides, the review demonstrates the importance of HCV in the development and progression of B-cell non-Hodgkin’s lymphomas, which is confirmed by its tumorigenicity. The paper reviews the variant of seronegative (occult) hepatitis С, which is characterized by HCV RNA detected in liver tissue and peripheral blood mononuclear cells by highly sensitive reverse transcription PCR with the absence of serum HCV and HCV RNA antibodies. In this case, patients can present a source of infection. Seronegative hepatitis С is detected in donor blood in 2.2–3.4 % of cases. This infection variant is identified in 20–85 % of oncohematological patients, which needs to be further examined. Comorbid HCV infection is a potential prognostic factor in oncohematological diseases. Oncohematological patients with comorbid chronic hepatitis C (CHC) show considerably worse survival as compared with patients without it. HCV infection is associated with increased complication rates in both chemotherapy and hematopoietic stem cell transplantation (HSCT). Immunochemotherapy, on the other hand, affects CHC exacerbation and progression. High efficacy and good tolerability of direct-acting antiviral agents (DAA) in CHC therapy opened new prospects for their wide use in cases of comorbid diseases. HCV treatment in patients after HSCT still remains an issue. The guidelines for CHC treatment are predominantly formulated with a view to antiviral pre-HSCT therapy which is not always feasible in real-world clinical practice. The review contains examples of effective use of DAA drugs before or after HSCT and a case of antiviral treatment administered simultaneously with HSCT.

show abstract

Section: противовирусное лечение хгс у онкогематологических пациентовunclassified

Chronic Hepatitis С and Oncohematological Diseases

Антонова,

Ножкин,

Лиознов

2024

Clinical Oncohematology

View full text Add to dashboard Cite

show abstract

“…Additionally, according to current guidelines all HCV-infected long-term survivors of HCT should be offered antiviral therapy 3 . However, little is known about the impact of treatment with these new drugs on the clinical course of HCV infection after transplantation [15][16][17][18][19] . In Brazil, data on HCV infection among HCT recipients is very scarce.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation

Diaz,

Witkin,

Almeida Neto

et al. 2024

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.

show abstract

Glecaprevir/pibrentasvir

2021

Reactions Weekly

View full text Add to dashboard Cite

Second direct-acting antiviral therapy for hepatitis C virus infection after umbilical cord blood transplantation: A case report

Cited by 3 publications

References 17 publications

Chronic Hepatitis С and Oncohematological Diseases

Chronic Hepatitis С and Oncohematological Diseases

Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation

Glecaprevir/pibrentasvir

Contact Info

Product

Resources

About